TG Therapeutics to Participate in the Evercore HealthCONx Conference
TG Therapeutics to Participate in the Evercore HealthCONx Conference
BRIUMVI is a registered trademark of TG Therapeutics, Inc.Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET
2024年12月3日星期二上午10:00举行的炉边谈话
NEW YORK, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the 7th Annual Evercore HealthCONx Conference, being held at the Loews Coral Gables Hotel, in Florida on December 3-5, 2024. The fireside chat is scheduled to take place on Tuesday, December 3, at 10:00 AM ET.
纽约，2024年11月29日（环球社会新闻）- tg therapeutics公司（纳斯达克股票代码：TGTX）今天宣布，公司董事长兼首席执行官Michael S. Weiss将参加于2024年12月3日至5日在佛罗里达州洛斯珊瑚盖布斯酒店举行的第七届Evercore HealthCONx会议。炉边谈话计划于2024年12月3日星期二上午10:00进行。
A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company's website at .
炉边谈话的现场网络广播将在公司网站的投资者与媒体页面上提供。
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit , and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
TG Therapeutics是一家完全集成、商业化阶段的生物制药公司，专注于收购、开发和商业化B细胞疾病的新型治疗方法。除了研究管线中包含几种调查药物外，TG还获得了美国食品和药品管理局的批准，使用BRIUMVI（ublituximab-xiiy）治疗复发性多发性硬化症的成人患者（RMS），包括临床分离综合征、复发缓解性疾病和活动性继发性疾病，以及欧洲委员会（EC）和药品和医疗保健产品监管局（MHRA）批准BRIUMVI用于治疗欧洲和英国分别具有临床或成像特征的RMS成人患者的活动性疾病。有关详细信息，请访问www.tgtherapeutics.com，并在X（前称Twitter）@TGTherapeutics上关注我们，并在
tg therapeutics是一家完全整合、具有商业阶段的生物制药公司，专注于收购、开发和商业化用于治疗B细胞疾病的新型治疗方法。除了拥有包括多种研究中药物在内的研发管线外，TG还获得了美国食品和药物管理局（FDA）批准用于治疗复发型多发性硬化（RMS）成年患者的BRIUMVI（ublituximab-xiiy）药物，包括临床孤立综合征、复发缓解性疾病和活跃次级进行性疾病患者，以及获得了欧洲委员会（EC）和英国药品和保健产品管制局（MHRA）批准用于治疗欧洲和英国有临床或影像特征定义的RMS患者具有活动性疾病的BRIUMVI。欲了解更多信息，请访问 ，并关注我们在X（以前的Twitter）@TGTherapeutics和LinkedIn。
BRIUMVI is a registered trademark of TG Therapeutics, Inc.
BRIUMVI是tg therapeutics注册商标。
CONTACT:
联系人：
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
投资者关系
电子邮件：ir@tgtxinc.com
电话：1.877.575.TGTX（8489），选项4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
媒体关系：
电子邮件：media@tgtxinc.com
电话：1.877.575.TGTX（8489），选项6
